FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and medicine, and concerns a pharmaceutical composition for treating cancer combined with preventing and/or treating side effects, comprising as active substance at least vincristine, paclitaxel or oxaliplatin and at least oxime cholest-4-en-3-one, or one of a derivatives thereof.
EFFECT: reducing side effects of the anti-cancer therapy.
9 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SIGMA-RECEPTOR LIGANDS FOR PREVENTING OR TREATING PAIN CAUSED BY CHEMOTHERAPY | 2010 |
|
RU2543382C2 |
| THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR MANAGING PAIN INDUSED BY AT LEAST ONE ANTI-CANCER AGENT | 2007 |
|
RU2483747C2 |
| USING COMPOUNDS BINDING TO SIGMA RECEPTOR LIGANDS FOR TREATING NEUROPATHIC PAIN PROGRESSION CAUSED BY CHEMOTHERAPY | 2009 |
|
RU2537226C2 |
| COMBINED CHEMOTHERAPY | 2001 |
|
RU2284818C2 |
| COMBINED CHEMOTHERAPY | 2006 |
|
RU2429838C2 |
| COMBINED CHEMOTHERAPY | 2010 |
|
RU2587013C2 |
| COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
| COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
